Clinical epidemiology of primary biliary cirrhosis: Incidence, prevalence, and impact of therapy

Journal of Clinical Gastroenterology

Volumn 41, Issue 5, 2007, Pages 494-500

  Lazaridis, Konstantinos N ^a,b   Talwalkar, Jayant A ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Biliary cirrhosis; Epidemiology; Natural history

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; COLCHICINE; METHOTREXATE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PREDNISONE; SILYMARIN; URSODEOXYCHOLIC ACID;

ANTIBODY DETECTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANADA; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE ACTIVITY; DISEASE TRANSMISSION; ENTERITIS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; INCIDENCE; LIVER TRANSPLANTATION; META ANALYSIS; MOLECULAR MIMICRY; MONOTHERAPY; PATHOGENESIS; POPULATION RESEARCH; PREGNANCY; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; SCANDINAVIA; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

CHOLAGOGUES AND CHOLERETICS; HUMANS; INCIDENCE; LIVER CIRRHOSIS, BILIARY; PREVALENCE; PROGNOSIS; RISK FACTORS; URSODEOXYCHOLIC ACID;

EID: 34247401795     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225653.07932.8f     Document Type: Review

References (89)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
2. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis. 2003;7:795-819.
3. Hamlyn A, Sherlock S. The epidemiology of primary biliary cirrhosis: a survey of mortality in England and Wales. Gut. 1974;15:473-479.
4. Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. Gut. 1983;24:940-945.
5. Hislop W. Primary biliary cirrhosis: an epidemiology study. BMJ. 1980;281:1069.
6. Triger DR. Primary biliary cirrhosis: an epidemiology study. BMJ. 1980;281:772-775.
7. Triger DR, Berg PA, Rodes J. Epidemiology of primary biliary cirrhosis. Liver. 1984;4:195-200.
8. Lofgren J, Jarnerot G, Danielsson D, et al. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. Scand J Gastroenterol. 1985;20:647-650.
9. Eriksson S, Lindgren S. The prevalence and clinical spectrum of primary biliary cirrhosis. Scand J Gastroenterol. 1984;19:971-976.
10. Balakrishnan V, Bhaskaran AS. Primary biliary cirrhosis with pruritus in India. Indian J Gastroenterol. 1997;16:121-122.
11. Goudie BM, Burt AD, Macfarlane GJ, et al. Risk factors and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 1989;84:713-716.
12. Danielsson A, Boqvist L, Uddenfeldt P. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology. 1990;11:458-464.
13. Myszor M, James OF. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? Q J Med. 1990;75:377-385.
14. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology. 1990;12: 98-105.
15. Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. Hepatology. 1991;13:650-655.
16. Villeneuve JP, Fenyves D, Infante-Rivard C. Descriptive epidemiology of primary biliary cirrhosis in the province of Quebec. Can J Gastroenterol. 1991;5:174-178.
17. Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr J Med Sci. 1992;28:683-687.
18. Remmel T, Remmel H, Uibo R, et al. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. Scand J Gastroenterol. 1995;30: 367-371.
19. Watson R, Angus P, Dewar M, et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Gut. 1995;36:927-930.
20. Anand AC, Elias E, Neuberger JM. End-stage primary biliary cirrhosis in a first generation migrant South Asian population. Eur J Gastroenterol Hepatol. 1996;8:663-666.
21. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology. 1996;24:813-815.
22. van Dam G, Gips C. Primary biliary cirrhosis (PBC) in an European country - a description of death rates in The Netherlands (1979-1992). Hepatogastroenterology. 1996;43:906-913.
23. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99-103.
24. Kingham JG, Parker DR. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut. 1998;42:120-122.
25. Metcalf J, Bhopal R, Gray J, et al. Incidence and prevalence of primary biliary cirrhosis in the City of Newcastle upon Tyne, England. Int J Epidemiol. 1997;26:830-836.
26. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology. 1999;30: 390-394.
27. Kim WR, Lindor KD, Locke GR III, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119:1631-1636.
28. Ray-Chadhuri D, Rigney E, McComack K, et al. Epidemiology of PBC in Sheffield Updated: Demographics and Relation to Water Supply. London: British Association for the Study of the Liver; 2001:42.
29. Hurlburt K, McMahon B, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402-2407.
30. Sood S, Gow PJ, Christie JM, et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology. 2004;127:470-475.
31. Chan CY, Lee SD, Huang YS, et al. Primary biliary cirrhosis in Taiwan. J Gastroenterol Hepatol. 1990;5:560-565.
32. Yap I, Weed A, Tay H, et al. Primary biliary cirrhosis - an uncommon disease in Singapore. Singapore Med J. 1996;37:48-50.
33. Bittencourt PL, Farias AQ, Abrantes-Lemos CP, et al. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2004;19:873-878.
34. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol. 1994;20:698-701.
35. Jones DE, Watt FE, Metcalf JV, et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol. 1999;30:402-407.
36. Tsuji K, Watanabe Y, van De Water J, et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun. 1999;13:171-178.
37. Prince M, Chetwynd A, Diggle P, et al. The geographical distribution of primary biliary cirrhosis in a well defined cohort. Hepatology. 2001;34:1083-1088.
38. Ala A, Stanca CM, Bu-Ghanim M, et al. Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology. 2006;43:525-531.
39. Talwalkar JA, Lazaridis KN. Polluting the pathogenesis of primary biliary cirrhosis. Hepatology. 2006;43:398-400.
40. Selmi C, Ichiki Y, Invernizzi P, et al. The enigma of primary biliary cirrhosis. Clin Rev Allergy Immunol. 2005;28:73-81.
41. Parikh-Patel A, Gold EB, Worman H, et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. Hepatology. 2001;33:16-21.
42. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42:1194-1202.
43. Howel D, Fischbacher CM, Bhopal RS, et al. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology. 2000;31:1055-1060.
44. Parikh-Patel A, Gold E, Utts J, et al. The association between gravidity and primary biliary cirrhosis. Ann Epidemiol. 2002;12:264-272.
45. Rigopoulou EI, Georgiadou SP, Barbanis S, et al. Lack of association between appendectomy and primary biliary cirrhosis. Scand J Gastroenterol. 2006;41:573-576.
46. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2003;7:779-794.
47. Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004;53:865-870.
48. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;1044:51-123.
49. Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology. 1980;236:46-78.
50. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989;10:1-7.
51. Springer J, Cauch-Dudek K, O'Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47-53.
52. Lucey MR, Neuberger JM, Williams R. Primary biliary cirrhosis in men. Gut. 1986;27:1373-1376.
53. Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol. 2004;2:1116-1122.
54. Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005;54:528-532.
55. Rigamonti C, Shand LM, Feudjo M, et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2006;55:388-394.
56. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013.
57. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol. 2001;35:134-146.
58. Leuschner U, Leuschner M, Sieratzki J, et al. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci. 1985;30:642-649.
59. Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987;1:834-836.
60. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989;97:1268-1274.
61. Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991;324:1548-1554.
62. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149-1156.
63. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284-1290.
64. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884-890.
65. Goulis J, Leandro G, Burroughs AK. Randomized controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354:1053-1060.
66. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2002;CD000551.
67. Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past - issues for the future. J Hepatol. 2000;32:685-688.
68. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut. 2000;46:121-126.
69. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999;117:918-925.
70. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;31:318-323.
71. Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol. 1998;29:736-742.
72. Jones EA, ten Kate FJ, terBorg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:1165-1169.
73. Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol. 1993;18:9-14.
74. Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology. 1995;22:1158-1162.
75. Gonzalez-Koch A, Brahm J, Antezana C, et al. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol. 1997;27:143-149.
76. Bonis PA, Kaplan M. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology. 1999;117:395-399.
77. Ikeda T, Tozuka S, Noguchi O, et al. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J Hepatol. 1996;24:88-94.
78. Poupon RE, Huet PM, Poupon R, et al. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology. 1996;24:1098-1103.
79. Battezzati PM, Zuin M, Crosignani A, et al. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Aliment Pharmacol Ther. 2001;15:1427-1434.
80. Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000;32:897-900.
81. Kurihara T, Niimi A, Maeda A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000;95:2990-2992.
82. Kurihara T, Maeda A, Shigemoto M, et al. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol. 2002;97:212-214.
83. Nakai S, Masaki T, Kurokohchi K, et al. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000;95:326-327.
84. Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644-647.
85. Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32:1196-1199.
86. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000;32:561-566.
87. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137-1140.
88. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297-303.
89. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-720.